Literature DB >> 15072994

Circulating tissue kallikrein levels correlate with severity of carotid atherosclerosis.

Paolo Porcu1, Costanza Emanueli, Elisa Desortes, Giovanni M Marongiu, Franco Piredda, Lee Chao, Julie Chao, Paolo Madeddu.   

Abstract

BACKGROUND: Vascular growth factors are upregulated in stroke patients, but it remains unknown if they correlate with carotid atherosclerosis. METHODS AND
RESULTS: A case-control study was conducted to determine: (1) possible association between biomarkers of angiogenesis or inflammation and carotid stenosis; and (2) the impact of revascularization on the same biomarkers. Circulating vascular endothelial growth factor (VEGF), basic fibroblast GF (bFGF), tissue kallikrein (tK), and high-sensitivity C-reactive protein (hs-CRP) were measured in 89 patients with carotid obstruction and 45 age-matched controls. Patients were stratified as <50% carotid stenosis (CAS; n=16); 50% to 69% CAS (n=12); 70% to 99% CAS (n=43); and carotid occlusion (CAO; n=18). No association was found between VEGF, bFGF, or hs-CRP and obstruction grading. TK augmented from 360+/-30 in <50% CAS (P=NS versus controls) to 509+/-72 in moderate CAS (P<0.05), 1159+/-178 in high-grade CAS (P<0.02), and 1616+/-403 pg/mL in CAO (P<0.01). A threshold of 508 pg/mL provided the maximized predictive value of high-grade obstruction. After revascularization, tK decreased from 1410+/-352 to 782+/-86 pg/mL (P<0.01), whereas no change was detected in nonoperated cases. Hs-CRP was unaffected by revascularization.
CONCLUSIONS: Angiogenic factors are heterogeneously expressed in patients with carotid atherosclerosis. The tK measurement may be useful for the diagnosis and monitoring of atherosclerotic disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15072994     DOI: 10.1161/01.ATV.0000128126.57688.a9

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  5 in total

1.  Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients.

Authors:  Milica Bozic; Angels Betriu; Marcelino Bermudez-Lopez; Alberto Ortiz; Elvira Fernandez; Jose M Valdivielso
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-08       Impact factor: 8.237

2.  Role of human tissue kallikrein in gastrointestinal stromal tumour invasion.

Authors:  P Dominek; P Campagnolo; M H-Zadeh; N Kränkel; M Chilosi; J A Sharman; A Caporali; G Mangialardi; G Spinetti; C Emanueli; M Pignatelli; P Madeddu
Journal:  Br J Cancer       Date:  2010-09-21       Impact factor: 7.640

3.  Role of kinin B2 receptor signaling in the recruitment of circulating progenitor cells with neovascularization potential.

Authors:  Nicolle Kränkel; Rajesh G Katare; Mauro Siragusa; Luciola S Barcelos; Paola Campagnolo; Giuseppe Mangialardi; Orazio Fortunato; Gaia Spinetti; Nguyen Tran; Kai Zacharowski; Wojciech Wojakowski; Iwona Mroz; Andrew Herman; Jocelyn E Manning Fox; Patrick E MacDonald; Joost P Schanstra; Jean Loup Bascands; Raimondo Ascione; Gianni Angelini; Costanza Emanueli; Paolo Madeddu
Journal:  Circ Res       Date:  2008-10-16       Impact factor: 17.367

4.  KLK1 and ZG16B proteins and arginine-proline metabolism identified as novel targets to monitor atherosclerosis, acute coronary syndrome and recovery.

Authors:  Marta Martin-Lorenzo; Irene Zubiri; Aroa S Maroto; Laura Gonzalez-Calero; Maria Posada-Ayala; Fernando de la Cuesta; Laura Mourino-Alvarez; Luis F Lopez-Almodovar; Eva Calvo-Bonacho; Luis M Ruilope; Luis R Padial; Maria G Barderas; Fernando Vivanco; Gloria Alvarez-Llamas
Journal:  Metabolomics       Date:  2014-12-14       Impact factor: 4.290

5.  Tissue Kallikrein Prevents Restenosis After Stenting of Severe Atherosclerotic Stenosis of the Middle Cerebral Artery: A Randomized Controlled Trial.

Authors:  Ruifeng Shi; Renliang Zhang; Fang Yang; Min Lin; Min Li; Ling Liu; Qin Yin; Hang Lin; Yunyun Xiong; Wenhua Liu; Xiaobing Fan; Qiliang Dai; Lizhi Zhou; Wenya Lan; Qinqin Cao; Xin Chen; Gelin Xu; Xinfeng Liu
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.